⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Official Title: A Phase 1/2a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of JAB-21822 in Combination With JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Study ID: NCT05288205

Interventions

JAB-21822
JAB-3312

Study Description

Brief Summary: This is a multicenter, open-label phase 1/2a study consisting of two parts: dose escalation phase and dose expansion phase. The objective of the dose escalation phase is to evaluate the safety, tolerability and pharmacokinetics of JAB-21822 in combination with JAB-3312 in patients with advanced solid tumors harboring KRAS p.G12C mutation and to determine the RP2D for the combination therapy. In the dose expansion phase, preliminary efficacy and safety of the combination therapy at the RP2D will be further explored in patients with specific cancer harboring KRAS p.G12C mutation.

Detailed Description:

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Pecking Union Medical College Hospital, Beijing, Beijing, China

Cancer Hospital Chinese Academy Of Medical Sciences, Beijing, Beijing, China

Beijing Tiantan Hospital, Captal Medical University, Beijing, Beijing, China

Beijing Cancer Hospital, Beijing, Beijing, China

Peking University Third Hospital, Beijing, Beijing, China

Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China

Fujian cancer Hospital, Fuzhou, Fujian, China

Cancer Hospital Chinese Academy Of medical Sciences Shenzhen Center, Shenzhen, Guangdong, China

Harbin Medical University Cancer Hospital-Mammary gland of internal, Ha'erbin, Heilongjiang, China

Henan Cancer Hospital, Zhengzhou, Henan, China

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China

Tongji Hospital Tongji Medical College of Hust, Wuhan, Hubei, China

Renmin Hospital Of Wuhan University, Wuhan, Hubei, China

Xiangya Hospital Central South Univesity, Changsha, Hunan, China

Hunan Cancer Hospital, Changsha, Hunan, China

The Second Hospital of Dalian Medical University, Dalian, Liaoning, China

The First Hospital Of China Medical University, Shenyang, Liaoning, China

Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China

The Affilated Hospital of Inner Mongolia Medical University, Hohhot, Neimenggu, China

Qilu Hospital of Shandong University, Jinan, Shandong, China

Shandong Cancer Hospital, Jinan, Shandong, China

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

The First Affiliated Hospital of Xi'An Jiaotong University, Xi'an, Shanxi, China

West China Hospital Sichuan University, Chendu, Sichuan, China

Contact Details

Name: Jacobio Pharmaceuticals

Affiliation: Jacobio Pharmaceuticals

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: